Relief Therapeutics Holding AG (RLFTF): MORE ON VIP INFUSIONS ——

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	30
Posts	1475
Boards Moderated	0
Alias Born	07/10/2013

changes_iv

Re: None

Monday, 08/02/2021 7:28:31 AM

Monday, August 02, 2021 7:28:31 AM

MORE ON VIP INFUSIONS ——— Dialysis requiring renal failure is a silent epidemic. Despite an annual mortality of 24% the dialysis population has increased by 1–4% per annum. Regardless of the initial injury, tubulointerstitial fibrosis is a feature of the renal pathology and it inversely correlates with declining renal function. Current agents display little efficacy against tubulointerstitial fibrosis. Clearly, therapies effective against tubulointerstitial fibrosis and able to preserve kidney function are needed. Vasoactive intestinal peptide (VIP) has been shown to reverse pre-existing cardiac fibrosis.

https://www.sciencedirect.com/science/article/pii/S0014299920300716

The global market for chronic kidney disease should grow from $79.0 billion in 2018 to reach $95.0 billion by 2023 at a compound annual growth rate (CAGR) of 3.8% for the period of 2018-2023.

https://www.bccresearch.com/market-research/healthcare/chronic-kidney-disease-market-research-report.html